{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:03:22Z","timestamp":1784822602800,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00949-5","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T14:00:56Z","timestamp":1779458456000},"page":"1789-1806","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond B Cell Depletion: Adhesion and Activation Network Remodeling During Repeated Intravenous Anti-CD20 Therapy in Multiple Sclerosis"],"prefix":"10.1007","volume":"15","author":[{"given":"Julia","family":"Feige","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Akg\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Schwenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hitzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjalf","family":"Ziemssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8749-5533","authenticated-orcid":false,"given":"Johann","family":"Sellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"8","key":"949_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"325","author":"MP McGinley","year":"2021","unstructured":"McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325(8):765\u201379.","journal-title":"JAMA"},{"issue":"23","key":"949_CR2","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1016\/j.febslet.2011.04.066","volume":"585","author":"C Larochelle","year":"2011","unstructured":"Larochelle C, Alvarez JI, Prat A. How do immune cells overcome the blood-brain barrier in multiple sclerosis? FEBS Lett. 2011;585(23):3770\u201380.","journal-title":"FEBS Lett"},{"issue":"2","key":"949_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0165-5728(99)00084-3","volume":"98","author":"SJ Lee","year":"1999","unstructured":"Lee SJ, Benveniste EN. Adhesion molecule expression and regulation on cells of the central nervous system. J Neuroimmunol. 1999;98(2):77\u201388.","journal-title":"J Neuroimmunol"},{"issue":"11","key":"949_CR4","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1158\/2326-6066.CIR-14-0161","volume":"2","author":"ML Dustin","year":"2014","unstructured":"Dustin ML. The immunological synapse. Cancer Immunol Res. 2014;2(11):1023\u201333.","journal-title":"Cancer Immunol Res"},{"key":"949_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cellimm.2018.10.006","volume":"339","author":"A Negron","year":"2019","unstructured":"Negron A, Robinson RR, St\u00fcve O, Forsthuber TG. The role of B cells in multiple sclerosis: current and future therapies. Cell Immunol. 2019;339:10\u201323.","journal-title":"Cell Immunol"},{"issue":"1","key":"949_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41579-022-00770-5","volume":"21","author":"SS Soldan","year":"2023","unstructured":"Soldan SS, Lieberman PM. Epstein-Barr virus and multiple sclerosis. Nat Rev Microbiol. 2023;21(1):51\u201364.","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"949_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus Interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221\u201334.","journal-title":"N Engl J Med"},{"issue":"1","key":"949_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00415-020-10362-z","volume":"269","author":"CG Chisari","year":"2022","unstructured":"Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F. Rituximab for the treatment of multiple sclerosis: a review. J Neurol. 2022;269(1):159\u201383.","journal-title":"J Neurol"},{"issue":"2","key":"949_CR9","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4049\/jimmunol.1400118","volume":"193","author":"A Palanichamy","year":"2014","unstructured":"Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser SL, et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol. 2014;193(2):580\u20136.","journal-title":"J Immunol"},{"issue":"1","key":"949_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/cells8010012","volume":"8","author":"S Gingele","year":"2018","unstructured":"Gingele S, Jacobus TL, Konen FF, H\u00fcmmert MW, S\u00fchs KW, Schwenkenbecher P, et al. Ocrelizumab depletes CD20\u207a T cells in multiple sclerosis patients. Cells. 2018;8(1):12.","journal-title":"Cells"},{"issue":"3","key":"949_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209\u201320.","journal-title":"N Engl J Med."},{"issue":"4","key":"949_CR12","doi-asserted-by":"publisher","first-page":"102492","DOI":"10.1016\/j.autrev.2020.102492","volume":"19","author":"J Sellner","year":"2020","unstructured":"Sellner J, Rommer PS. Immunological consequences of \u201cimmune reconstitution therapy\u201d in multiple sclerosis: a systematic review. Autoimmun Rev. 2020;19(4):102492.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"949_CR13","doi-asserted-by":"publisher","first-page":"e940","DOI":"10.1212\/NXI.0000000000000940","volume":"8","author":"JI Fern\u00e1ndez-Velasco","year":"2021","unstructured":"Fern\u00e1ndez-Velasco JI, Kuhle J, Monreal E, Meca-Lallana V, Meca-Lallana J, Izquierdo G, et al. Effect of Ocrelizumab in blood leukocytes of patients with primary progressive MS. Neurol Neuroimmunol Neuroinflamm. 2021;8(2):e940.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"949_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/mabs.22771","volume":"5","author":"C Klein","year":"2013","unstructured":"Klein C, Lammens A, Sch\u00e4fer W, Georges G, Schwaiger M, M\u00f6ssner E, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013;5(1):22\u201333.","journal-title":"MAbs"},{"key":"949_CR15","doi-asserted-by":"publisher","first-page":"953649","DOI":"10.3389\/fimmu.2022.953649","volume":"13","author":"A Mariottini","year":"2022","unstructured":"Mariottini A, Muraro PA, L\u00fcnemann JD. Antibody-mediated cell depletion therapies in multiple sclerosis. Front Immunol. 2022;13:953649.","journal-title":"Front Immunol"},{"issue":"11","key":"949_CR16","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.3390\/cells10113177","volume":"10","author":"S Fischer","year":"2021","unstructured":"Fischer S, Proschmann U, Akg\u00fcn K, Ziemssen T. Lymphocyte counts and multiple sclerosis therapeutics: between mechanisms of action and treatment-limiting side effects. Cells. 2021;10(11):3177.","journal-title":"Cells"},{"key":"949_CR17","doi-asserted-by":"publisher","first-page":"123303","DOI":"10.1016\/j.jns.2024.123303","volume":"467","author":"SA Kornilov","year":"2024","unstructured":"Kornilov SA, Price ND, Gelinas R, Acosta J, Brunkow ME, Gervasi-Follmar T, et al. Multi-omic characterization of the effects of Ocrelizumab in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2024;467:123303.","journal-title":"J Neurol Sci"},{"issue":"1","key":"949_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","volume":"175","author":"I Jelcic","year":"2018","unstructured":"Jelcic I, Al Nimer F, Wang J, Lentsch V, Planas R, Jelcic I, et al. Memory B cells activate brain-homing, autoreactive CD4(+) T cells in multiple sclerosis. Cell. 2018;175(1):85-100.e23.","journal-title":"Cell"},{"issue":"10","key":"949_CR19","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1002\/acn3.52182","volume":"11","author":"M Waede","year":"2024","unstructured":"Waede M, Voss LF, Kingo C, Moeller JB, Elkjaer ML, Illes Z. Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti-CD20 therapy. Ann Clin Transl Neurol. 2024;11(10):2657\u201372.","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"949_CR20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/acn3.51965","volume":"11","author":"J Feige","year":"2024","unstructured":"Feige J, Moser T, Akg\u00fcn K, Schwenker K, Hitzl W, Haschke-Becher E, et al. Repeated iv anti-CD20 treatment in multiple sclerosis: long-term effects on peripheral immune cell subsets. Ann Clin Transl Neurol. 2024;11(2):450\u201365.","journal-title":"Ann Clin Transl Neurol"},{"issue":"11","key":"949_CR21","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1002\/acn3.51206","volume":"7","author":"T Moser","year":"2020","unstructured":"Moser T, Schwenker K, Seiberl M, Feige J, Akgun K, Haschke-Becher E, et al. Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS. Ann Clin Transl Neurol. 2020;7(11):2199\u2013212.","journal-title":"Ann Clin Transl Neurol"},{"issue":"41","key":"949_CR22","doi-asserted-by":"publisher","first-page":"25690","DOI":"10.1073\/pnas.2012249117","volume":"117","author":"N Nissimov","year":"2020","unstructured":"Nissimov N, Hajiyeva Z, Torke S, Grondey K, Br\u00fcck W, H\u00e4usser-Kinzel S, et al. B cells reappear less mature and more activated after their anti-CD20-mediated depletion in multiple sclerosis. Proc Natl Acad Sci U S A. 2020;117(41):25690\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"39","key":"949_CR23","doi-asserted-by":"publisher","first-page":"9773","DOI":"10.1073\/pnas.1810470115","volume":"115","author":"D H\u00e4usler","year":"2018","unstructured":"H\u00e4usler D, H\u00e4usser-Kinzel S, Feldmann L, Torke S, Lepennetier G, Bernard CCA, et al. Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease. Proc Natl Acad Sci U S A. 2018;115(39):9773\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 1(Suppl 1","key":"949_CR24","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/ar3908","volume":"15","author":"MJ Leandro","year":"2013","unstructured":"Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther. 2013;15(Suppl 1(Suppl 1)):S3.","journal-title":"Arthritis Res Ther"},{"key":"949_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cells14070552","author":"AG Willison","year":"2025","unstructured":"Willison AG, Hagler R, Weise M, Elben S, Huntemann N, Masanneck L, et al. Effects of Anti-CD20 antibody therapy on immune cell dynamics in Relapsing-Remitting Multiple Sclerosis. Cells. 2025. https:\/\/doi.org\/10.3390\/cells14070552.","journal-title":"Cells"},{"issue":"4","key":"949_CR26","doi-asserted-by":"publisher","first-page":"e200250","DOI":"10.1212\/NXI.0000000000200250","volume":"11","author":"G Abbadessa","year":"2024","unstructured":"Abbadessa G, Lepore MT, Bruzzaniti S, Piemonte E, Miele G, Signoriello E, et al. Ocrelizumab alters cytotoxic lymphocyte function while reducing EBV-specific CD8(+) T-cell proliferation in patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2024;11(4):e200250.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"949_CR27","doi-asserted-by":"publisher","first-page":"663","DOI":"10.4103\/1673-5374.266913","volume":"15","author":"S Gingele","year":"2020","unstructured":"Gingele S, Skripuletz T, Jacobs R. Role of CD20(+) T cells in multiple sclerosis: implications for treatment with ocrelizumab. Neural Regen Res. 2020;15(4):663\u20134.","journal-title":"Neural Regen Res"},{"issue":"14","key":"949_CR28","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1177\/13524585211003301","volume":"27","author":"Q Howlett-Prieto","year":"2021","unstructured":"Howlett-Prieto Q, Feng X, Kramer JF, Kramer KJ, Houston TW, Reder AT. Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis. Mult Scler. 2021;27(14):2170\u20139.","journal-title":"Mult Scler"},{"key":"949_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26146655","author":"AC Mazzeo","year":"2025","unstructured":"Mazzeo AC, Calabresi L, Damato V, Spagni G, Massacesi L, Mariottini A. CD20+ T cells in Multiple Sclerosis: from pathogenesis to treatment-induced depletion. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26146655.","journal-title":"Int J Mol Sci"},{"key":"949_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3389\/fimmu.2013.00107","volume":"4","author":"MA Moro-Garc\u00eda","year":"2013","unstructured":"Moro-Garc\u00eda MA, Alonso-Arias R, L\u00f3pez-Larrea C. When aging reaches CD4+ T-cells: phenotypic and functional changes. Front Immunol. 2013;4:107.","journal-title":"Front Immunol"},{"issue":"6","key":"949_CR31","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40263-014-0160-8","volume":"28","author":"RA Du Pasquier","year":"2014","unstructured":"Du Pasquier RA, Pinschewer DD, Merkler D. Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis. CNS Drugs. 2014;28(6):535\u201358.","journal-title":"CNS Drugs"},{"issue":"6","key":"949_CR32","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1212\/NXI.0000000000000401","volume":"4","author":"A Mathias","year":"2017","unstructured":"Mathias A, Perriot S, Canales M, Blatti C, Gaubicher C, Schluep M, et al. Impaired T-cell migration to the CNS under fingolimod and dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm. 2017;4(6):e401.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"949_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cells10113116","author":"T Moser","year":"2021","unstructured":"Moser T, Hoepner L, Schwenker K, Seiberl M, Feige J, Akg\u00fcn K, et al. Cladribine alters immune cell surface molecules for adhesion and costimulation: further insights to the mode of action in Multiple Sclerosis. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10113116.","journal-title":"Cells"},{"key":"949_CR34","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200083","author":"S Ho","year":"2023","unstructured":"Ho S, Oswald E, Wong HK, Vural A, Yilmaz V, T\u00fcz\u00fcn E, et al. Ocrelizumab treatment modulates B-cell regulating factors in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023. https:\/\/doi.org\/10.1212\/NXI.0000000000200083.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"949_CR35","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2174\/0113816128288102240131053205","volume":"30","author":"SN Deftereos","year":"2024","unstructured":"Deftereos SN, Vavougios GD, Bakirtzis C, Hadjigeorgiou G, Grigoriadis N. Effects of high efficacy multiple sclerosis disease modifying drugs on the immune synapse: a systematic review. Curr Pharm Des. 2024;30(7):536\u201351.","journal-title":"Curr Pharm Des"},{"issue":"2","key":"949_CR36","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1177\/13524585221109386","volume":"29","author":"I Smets","year":"2023","unstructured":"Smets I, Wokke B, Smolders J. Should anti-CD20 be used as an immune reconstitution therapy? Mult Scler. 2023;29(2):308\u201310.","journal-title":"Mult Scler"},{"issue":"9","key":"949_CR37","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40263-021-00843-8","volume":"35","author":"A Bar-Or","year":"2021","unstructured":"Bar-Or A, O\u2019Brien SM, Sweeney ML, Fox EJ, Cohen JA. Clinical perspectives on the molecular and pharmacological attributes of Anti-CD20 therapies for Multiple Sclerosis. CNS Drugs. 2021;35(9):985\u201397.","journal-title":"CNS Drugs"},{"issue":"4","key":"949_CR38","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00415-023-12007-3","volume":"271","author":"SR Delgado","year":"2024","unstructured":"Delgado SR, Faissner S, Linker RA, Rammohan K. Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for Multiple Sclerosis treatment. J Neurol. 2024;271(4):1515\u201335.","journal-title":"J Neurol"},{"issue":"9","key":"949_CR39","doi-asserted-by":"publisher","first-page":"4497","DOI":"10.4049\/jimmunol.170.9.4497","volume":"170","author":"A Alter","year":"2003","unstructured":"Alter A, Duddy M, Hebert S, Biernacki K, Prat A, Antel JP, et al. Determinants of human B cell migration across brain endothelial cells. J Immunol. 2003;170(9):4497\u2013505.","journal-title":"J Immunol"},{"key":"949_CR40","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3389\/fimmu.2018.00952","volume":"9","author":"BL Walling","year":"2018","unstructured":"Walling BL, Kim M. LFA-1 in T cell migration and differentiation. Front Immunol. 2018;9:952.","journal-title":"Front Immunol"},{"issue":"3","key":"949_CR41","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.bbadis.2015.10.004","volume":"1862","author":"MA L\u00e9cuyer","year":"2016","unstructured":"L\u00e9cuyer MA, Kebir H, Prat A. Glial influences on BBB functions and molecular players in immune cell trafficking. Biochim Biophys Acta. 2016;1862(3):472\u201382.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"949_CR42","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1600-0404.1998.tb01727.x","volume":"98","author":"J Kraus","year":"1998","unstructured":"Kraus J, Oschmann P, Engelhardt B, Schiel C, Hornig C, Bauer R, et al. Soluble and cell surface ICAM-1 as markers for disease activity in multiple sclerosis. Acta Neurol Scand. 1998;98(2):102\u20139.","journal-title":"Acta Neurol Scand."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00949-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00949-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00949-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:16Z","timestamp":1784819476000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00949-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["949"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00949-5","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"21 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Julia Feige received travel support, honoraria for presentations or participation on advisory boards from Novartis, Roche, Sanofi, Merck, and AbbVie. Tobias Moser received travel support, honoraria for presentations or participation on advisory boards from Biogen, BMS, Novartis, Roche, Sanofi, Merck, Stada, and Teva. Katja Akg\u00fcn received personal compensation from Novartis, Biogen Idec, Teva, Sanofi, and Roche for consulting services. Tjalf Ziemssen reports scientific advisory board and\/or consulting for Biogen, Roche, Novartis, Celgene, and Merck; compensation for serving on speaker\u00b4s bureaus for Roche, Novartis, Merck, Sanofi, Celgene, and Biogen; and research support from Biogen, Novartis, Merck, and Sanofi. Johann Sellner received travel support, honoraria for presentations or participation on advisory boards from Angelini, Eisai, Gerot-Lannach, Lundbeck, Neuraxpharm, Novartis, Roche, Sandoz, Schwabe, and Takeda. Kerstin Schwenker, and Wolfgang Hitzl have nothing to disclose. Johann Sellner is an editorial board member of\n                      Neurology and Therapy\n                      . Johann Sellner was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The procedures performed in our study were conducted in accordance with the ethical standards of the institutional and\/or national research committee, the 1964 Helsinki Declaration and its later amendments, or comparable ethical standards. All patients provided written informed consent for participation and subsequent publication of data after approval by the Ethics Committee of Bundesland Salzburg (415-E\/161 2111-2018). The study was carried out according to the Helsinki protocol in its current version.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}